Author:
Bello-Rivero Iraldo,Torrez-Ruiz Yeny,Blanco-Garcés Elizabeth,Pentón-Rol Giselle,Fernández-Batista Osmani,Javier-González Luís,Gerónimo-Perez Haydee,López-Saura Pedro
Abstract
Abstract
Background
TH1 immune response antagonism is a desirable approach to mitigate some autoimmune and inflammatory reactions during the course of several diseases where IL-2 and IFN-γ are two central players. Therefore, the neutralization of both cytokines could provide beneficial effects in patients suffering from autoimmune or inflammatory illnesses.
Results
A chimeric antagonist that can antagonize the action of TH1 immunity mediators, IFN-γ and IL-2, was designed, engineered, expressed in E. coli, purified and evaluated for its in vitro biological activities. The TH1 antagonist molecule consists of the extracellular region for the human IFNγ receptor chain 1 fused by a four-aminoacid linker peptide to human 60 N-terminal aminoacid residues of IL-2. The corresponding gene fragments were isolated by RT-PCR and cloned in the pTPV-1 vector. E. coli (W3110 strain) was transformed with this vector. The chimeric protein was expressed at high level as inclusion bodies. The protein was partially purified by pelleting and washing. It was then solubilized with strong denaturant and finally refolded by gel filtration. In vitro biological activity of chimera was demonstrated by inhibition of IFN-γ-dependent HLA-DR expression in Colo 205 cells, inhibition of IFN-γ antiproliferative effect on HEp-2 cells, and by a bidirectional effect in assays for IL-2 T-cell dependent proliferation: agonism in the absence versus inhibition in the presence of IL-2.
Conclusion
TH1 antagonist is a chimeric protein that inhibits the in vitro biological activities of human IFN-γ, and is a partial agonist/antagonist of human IL-2. With these attributes, the chimera has the potential to offer a new opportunity for the treatment of autoimmune and inflammatory diseases.
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Farrar MA, Schreiber RD: The molecular cell biology of interferon gamma and its receptor. Ann Rev Immunol. 1993, 11: 571-611. 10.1146/annurev.iy.11.040193.003035.
2. Chan SH, Kobayashi M, Santoli D, Perussia B, Trinchieri G: Mechanisms of IFN-induction by natural killer cell stimulatory factor (NKSF/IL-12): role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol. 1992, 148: 92-98.
3. Trinchieri G, Perussia B: Immune Interferon: A pleiotropic lymphokine with multiple effects. Immunol Today. 1985, 6: 131-136. 10.1016/0167-5699(85)90080-5.
4. Revel M, Chebath J: Interferon-activated genes. TIBS. 1986, 11: 166-170.
5. Bach EA, Aguet M, Schreiber RD: The IFN gamma receptor: A paradigm for cytokine signaling. Annu Rev Immunol. 1997, 15: 563-591. 10.1146/annurev.immunol.15.1.563.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献